Trending Topic

20 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Article highlights There is growing clinical importance attributed to the development of metabolic dysfunction-associated steatotic liver disease in people with type 2 diabetes (T2D). Numerous international groups now advocate screening for advanced fibrosis in people with risk factors, such as T2D, using non-invasive biomarkers. This article explores the rationale to screen for advanced fibrosis in people with risk […]

Irene Lambrinoudaki, WCO21: Treatment of Menopausal and Vulvovaginal Atrophy Symptoms and Menopausal Hormone Therapy in Treating Menopause-associated Bone Loss

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Oct 1st 2021

touchENDOCRINOLOGY joins Professor Irene Lambrinoudaki (National and Kapodistrian University of Athens, Greece), at WCO21 to discuss her presentation on the treatment of menopausal and vulvovaginal atrophy symptoms, and menopausal hormone therapy in treating menopause-associated bone loss.

Questions
1. How are bothersome menopausal and vulvovaginal atrophy symptoms currently treated? (00:30-02:00)
2. What are the benefits and risks of menopausal hormone therapy in treating menopause-associated bone loss, including factors which impact outcomes? (02:00-04:06)

Disclosures: Irene Lambrinoudak has no financial or non-financial conflicts of interest to declare in relation to this video.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.

Filmed in coverage of the WCO21 Annual Meeting.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup